Peijia Medical Limited (FRA:4WO)

Market Cap	454.67M +24.6%
Revenue (ttm)	86.81M +15.8%
Net Income	-24.75M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	168.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	375
Open	0.6450
Previous Close	0.6150
Day's Range	0.6450 - 0.6450
52-Week Range	0.4840 - 1.0100
Beta	n/a
RSI	56.08
Earnings Date	Mar 25, 2026

About Peijia Medical

Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People’s Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company's products include transcatheter aortic valve replacement (TAVR) systems, crosslinked dry-tissue and polymeric tri leaflet TAVR systems, transcatheter aortic valve s...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2012
• Employees: 1,035
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4WO

Financial Performance

In 2025, Peijia Medical's revenue was 712.87 million, an increase of 15.82% compared to the previous year's 615.48 million. Losses were -203.29 million, -10.28% less than in 2024.

Financial numbers in CNY